5/24/2013

Acumen Pharmaceuticals has pulled in $20 million in a Series A funding round from BVF Partners, NeuroVentures Fund and other investors. Proceeds will go toward preclinical development of the firm's Alzheimer's disease drug candidate, an antibody that targets soluble oligomers of the amyloid beta peptide in the brain.

Full Story:
MedCityNews.com

Related Summaries